The Opportunity: SFC Fluidics is seeking a $650,000 investment to achieve key regulatory and clinical milestones for its PANDA™ insulin delivery system within the next nine months. The company’s valuation is set at $30M, for this raise with a projected appreciation of 15X or more upon successful completion of these milestones.SFC Fluidics is seeking a $650,000 investment to achieve key regulatory and clinical milestones for its PANDA™ insulin delivery system within the next nine months. The company’s valuation is set at $30M, for this raise with a projected appreciation of 15X or more upon successful completion of these milestones.

The PANDA system is a next-generation patch pump with a Breakthrough Designation from the FDA, which accelerates its regulatory review. It’s designed to overcome the limitations of current market leaders like Insulet and Medtronic by offering superior dosing accuracy, smaller size, and a safety-enhancing dispense confirmation sensor at a lower cost.

The investment will be used to complete the 510(k) submission for the PANDA system, a process that historically has led to significant valuation increases for insulin pump companies. SFC has already attracted the interest of large diabetes companies for potential partnerships after reaching regulatory and clinical milestones.  These discussions could lead to a lucrative exit for investors.  In addition, SFC is already negotiating agreements with two academic groups for the use of the PANDA system in human data studies starting in 1Q2026

Historically, valuation for insulin pump companies hit $150M or more based on regulatory submission alone.  Coupled with studies that provide human clinical data, valuations can reach substantially higher levels.  A comparable, EOFlow, was the subject of a $738M acquisition bid from Medtronic.  The deal did not materialize due to apparent IP issues, and Medtronic continues its pursuit of an insulin patch pump.